Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

2013-03

TMC435 is a potent, once-daily, investigational hepatitis C virus (HCV) NS3/4A protease inhibitor in phase III clinical development. In the phase II trial TMC435-C202 (NCT00812331), TMC435 displayed potent activity in genotype 4, 5 and 6 patients and in 3/6 genotype 2 patients, whereas no activity was observed with genotype 3.
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
info:eu-repo/semantics/published

Sciences bio-médicales et agricoles; Antiviral Agents -- therapeutic use; Genotype; Hepacivirus -- classification -- drug effects -- genetics; Hepatitis C -- drug therapy -- virology; Heterocyclic Compounds, 3-Ring -- pharmacology -- therapeutic use; Humans; Mutation; Polymorphism, Genetic; RNA, Viral -- blood; Sulfonamides -- pharmacology -- therapeutic use; Viral Nonstructural Proteins -- antagonists & inhibitors -- genetics; info:eu-repo/semantics/article; info:ulb-repo/semantics/articlePeerReview; info:ulb-repo/semantics/openurl/article

Open access content. Open access content
1 full-text file(s): info:eu-repo/semantics/restrictedAccess

1 full-text file(s): application/pdf
English

EQY oai:dipot.ulb.ac.be:2013/156155
uri/info:doi/10.1016/j.jhep.2012.10.028
uri/info:pii/S0168-8278(12)00829-X
uri/info:pmid/23142061
uri/info:scp/84874105854
872085127

UNIVERSITE LIBRE DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.

edsoai.ocn872085127